IDWeek 2020
AWG Member Company Participation at IDWeek 2020
Eight AWG member companies will present data from their clinical and research programs at the virtual IDWeek 2020 held October 21-25, with a total of 26 ePosters and 6 on-demand oral abstracts.
IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS) that brings together infectious disease professionals to present and discuss the latest approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
Session: STIs & UTIs
Oral Abstract
On-demand
Iterum Therapeutics:
- LB-1 – Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
Session: Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)
Poster Session
On-demand
Cidara Therapeutics:
- 43 – A Pharmacoepidemiologic Evaluation of Echinocandin Use
Session: Innovations and Updates in Mycology
Oral Abstract
On-demand
Amplyx Pharmaceuticals:
- 147 – Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
Session: Novel Vaccines and Antibodies
Oral Abstract
On-demand
Cidara Therapeutics:
- 159 – Efficacy of CD377, a Novel Antiviral Fc-conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models
- 162 – CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models
Session: Novel Agents
Oral Abstract
On-demand
Amplyx Pharmaceuticals:
- 168 – Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis
Qpex Biopharma:
- 166 – Activity of a Novel β-lactamase Inhibitor QPX7728 Combined With β-lactams Against st258 klebsiella Pneumoniae and st131 escherchia Coli Isolates Producing β-lactamases
Session: Clinical Trials
Poster Session
On-demand
Cidara Therapeutics:
- 637 – Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
Session: Eukaryotic Diagnostics
Poster Session
On-demand
SCYNEXIS:
- 733 – Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
Session: Medical Mycology
Poster Session
On-demand
Amplyx Pharmaceuticals:
- 1157 – Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-Class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
Cidara Therapeutics:
- 1174 – Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
Session: Microbial Pathogenesis
Poster Session
On-demand
Paratek Pharmaceuticals:
- 1202 – Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
Session: New Drug Development
Poster Session
On-demand
Iterum Therapeutics:
- 1232 – Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial
Session: Novel Agents
Poster Session
On-demand
Amplyx Pharmaceuticals:
- 1260 – Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type
- 1275 – Evaluation of in vitro Activity of Manogepix against Multidrug-resistant and Pan-resistant Candida auris from the New York Outbreak
- 1282 – Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates in vitro Activity Against Members of the Fusarium oxysporum and Fusarium solani Species Complexes
Cidara Therapeutics:
- 1276 – Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models
- 1283 – New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single
- 1284 – Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
- 1286 – Pharmacokinetics, Excretion, and Mass Balance of [14C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
Entasis Therapeutics:
- 1254 – In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates
- 1293 – Sulbactam-durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East
SCYNEXIS:
- 1248 – Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
- 1251 – Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
Venatorx Pharmaceuticals:
- 1263 – Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM)
Session: PK/PD Studies
Poster Session
On-demand
Venatorx Pharmaceuticals:
- 1318 – Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
Session: Respiratory Infections – Bacterial
Poster Session
On-demand
Entasis Therapeutics:
- 1490 – Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review
Paratek Pharmaceuticals:
- 1492 – Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
Session: Treatment of Antimicrobial Resistant Infections
Poster Session
On-demand
Amplyx Pharmaceuticals:
- 1614 – Gwt1 Inhibitor, APX2104, Protects Against Invasive Aspergillosis in Neutropenic Mouse Model
Session: Tuberculosis and other Mycobacterial Infections
Poster Session
On-demand
Entasis Therapeutics:
- 1642 – A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)
Session: UTIs
Poster Session
On-demand
Paratek Pharmaceuticals:
- 1687 – Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study
- 1688 – Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study